Multimodal neuroimaging computing: a review of the applications in neuropsychiatric disorders

Liu, Sidong; Cai, Weidong; Zhang, Fan; Fulham, Michael; Feng, Dagan; Pujol, Sonia; Kikinis, Ron

doi:10.1007/s40708-015-0019-x

Cited by 133 publications

(73 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistently, in a recent review, Liu et al [23] proposed that multimodal neuroimaging analysis, identifying both the functional connections and their anatomical basis, may become a major driver for targeting disease and treatment/treatment response biomarkers with high sensitivity and specificity.…”

Section: Connectivity Within the Default Mode Networkmentioning

confidence: 88%

A Review of the Functional and Anatomical Default Mode Network in Schizophrenia

et al. 2016

View full text Add to dashboard Cite

Schizophrenia is a severe mental disorder characterized by impaired perception, delusions, thought disorder, abnormal emotion regulation, altered motor function, and impaired drive. The default mode network (DMN), since it was first proposed in 2001, has become a central research theme in neuropsychiatric disorders, including schizophrenia. In this review, first we define the DMN and describe its functional activity, functional and anatomical connectivity, heritability, and inverse correlation with the task positive network. Second, we review empirical studies of the anatomical and functional DMN, and anti-correlation between DMN and the task positive network in schizophrenia. Finally, we review preliminary evidence about the relationship between antipsychotic medications and regulation of the DMN, review the role of DMN as a treatment biomarker for this disease, and consider the DMN effects of individualized therapies for schizophrenia.

show abstract

Section: Connectivity Within the Default Mode Networkmentioning

confidence: 88%

A Review of the Functional and Anatomical Default Mode Network in Schizophrenia

et al. 2016

View full text Add to dashboard Cite

show abstract

“…A number of different modalities and techniques have been used to complement fMRI analysis, either simultaneously or separated in time, and have been reviewed elsewhere (Biessmann et al, 2011; Uludag and Roebroeck, 2014; Liu et al, 2015a; Garcés et al, 2016). One particularly powerful approach to better understanding the brain is to model it as a network of functional connections between every possible region.…”

Section: Multimodal Studiesmentioning

confidence: 99%

A Hitchhiker's Guide to Functional Magnetic Resonance Imaging

et al. 2016

View full text Add to dashboard Cite

Functional Magnetic Resonance Imaging (fMRI) studies have become increasingly popular both with clinicians and researchers as they are capable of providing unique insights into brain functions. However, multiple technical considerations (ranging from specifics of paradigm design to imaging artifacts, complex protocol definition, and multitude of processing and methods of analysis, as well as intrinsic methodological limitations) must be considered and addressed in order to optimize fMRI analysis and to arrive at the most accurate and grounded interpretation of the data. In practice, the researcher/clinician must choose, from many available options, the most suitable software tool for each stage of the fMRI analysis pipeline. Herein we provide a straightforward guide designed to address, for each of the major stages, the techniques, and tools involved in the process. We have developed this guide both to help those new to the technique to overcome the most critical difficulties in its use, as well as to serve as a resource for the neuroimaging community.

show abstract

“…Moreover, PET/SPECT imaging can also be used to identify whether a delay between plasma unbound drug concentrations and CNS effect is caused by slow target equilibration or by slow transduction processes. Dose (or plasma concentration)-TO curves can be obtained to guide the dosing in clinical trials [50][51][52].…”

Section: Target Binding Kineticsmentioning

confidence: 99%

“…These techniques are increasingly employed in assessing the pathophysiological changes in different disease states, such as target expression, release of endogenous ligands that bind the drug target (e.g. neurotransmitters), neuroinflammation/glial activation, cerebral blood flow, and BBB integrity, all of which could alter the drug PK, TO, and biomarker profiles [50][51][52].…”

Section: Biomarkers Of Drug Effects and Diseasementioning

confidence: 99%

Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics

Lange

Brink

Yamamoto

et al. 2017

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

Introduction: CNS drug development has been hampered by inadequate consideration of CNS pharmacokinetic (PK), pharmacodynamics (PD) and disease complexity (reductionist approach). Improvement is required via integrative model-based approaches. Areas covered: The authors summarize factors that have played a role in the high attrition rate of CNS compounds. Recent advances in CNS research and drug discovery are presented, especially with regard to assessment of relevant neuro-PK parameters. Suggestions for further improvements are also discussed. Expert opinion: Understanding time-and condition dependent interrelationships between neuro-PK and neuro-PD processes is key to predictions in different conditions. As a first screen, it is suggested to use in silico/in vitro derived molecular properties of candidate compounds and predict concentrationtime profiles of compounds in multiple compartments of the human CNS, using time-course based physiology-based (PB) PK models. Then, for selected compounds, one can include in vitro drug-target binding kinetics to predict target occupancy (TO)-time profiles in humans. This will improve neuro-PD prediction. Furthermore, a pharmaco-omics approach is suggested, providing multilevel and paralleled data on systems processes from individuals in a systems-wide manner. Thus, clinical trials will be better informed, using fewer animals, while also, needing fewer individuals and samples per individual for proof of concept in humans. ARTICLE HISTORY

show abstract

Multimodal neuroimaging computing: a review of the applications in neuropsychiatric disorders

Cited by 133 publications

References 111 publications

A Review of the Functional and Anatomical Default Mode Network in Schizophrenia

A Review of the Functional and Anatomical Default Mode Network in Schizophrenia

A Hitchhiker's Guide to Functional Magnetic Resonance Imaging

Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics

Contact Info

Product

Resources

About